{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '49', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Objectives', 'Enppoints', 'Tertiary/Exploratory', 'Objective: To compare the PFS and ORR', 'PFS, defined as the time from', 'per adjusted RECIST 1.1 for Immune-', 'randomization to the first documented', 'based Therapeutics (iRECIST) as', 'PD or death due to any cause, whichever', 'assessed by the investigator for the', 'occurs first', 'combinations of pembrolizumab +', 'OR, defined as a confirmed CR or PR', 'lenvatinib versus pembrolizumab +', 'matching placebo', 'Objective: To evaluate DOR per RECIST', 'DOR, defined as the time from the', '1.1, as defined in Section 4.2.1.1.1, for', 'earliest date of qualifying response until', 'the combinations of pembrolizumab +', 'earliest date of PD or death from any', 'lenvatinib and pembrolizumab +', 'cause, whichever comes first', 'matching placebo', 'Objective: To evaluate and compare', 'Health utilities assessed using the', \"participant's health status as assessed by\", 'EuroQoL EQ-5D-5L', 'the EuroQoL 5 Dimensions 5-Level (EQ-', '5D-5L) questionnaire to generate utility', 'scores for use in economic models', 'Objective: To evaluate the', 'Plasma concentration of lenvatinib', 'pharmacokinetics (PK) of lenvatinib', 'versus time', 'when coadministered with', 'pembrolizumab', 'To identify molecular (genomic,', 'Molecular (genomic, metabolic, and/or', 'metabolic, and/or proteomic) biomarkers', 'proteomic) determinants of response or', 'that may be indicative of clinical', 'resistance to treatments, using blood', 'response/resistance, safety, and/or the', 'and/or tumor tissue', 'mechanism of action of pembrolizumab', 'and lenvatinib in all participants', '*This study will be considered to have met its success criteria if the combination of', 'pembrolizumab + lenvatinib is superior to pembrolizumab + matching placebo in PFS or OS.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '50', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4', 'STUDY DESIGN', '4.1', 'Overall Design', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Participants who remain on treatment will receive open-label', 'pembrolizumab monotherapy, as per protocol. The Second-course Treatment Phase is', 'removed from the study. This section has been updated accordingly.', 'The original study design was a randomized, double-blind, active-control with placebo,', 'parallel-group, multisite study of IV pembrolizumab and oral lenvatinib in participants with', 'Stage IV NSCLC and PD-L1 TPS 1% who have not had previously received systemic', 'therapy for metastatic disease, whose tumors express PD-L1 with a TPS 1%, and in whom', 'EGFR-, ALK-, or ROS proto-oncogene 1 (ROS1)-directed therapy is not indicated.', 'Participants were randomized 1:1 to Arm A (pembrolizumab + lenvatinib) or Arm B', '(pembrolizumab + matching placebo). Randomization was stratified by site geographic', 'region (East Asia VS non-East Asia), ECOG PS (0 VS 1), and TPS (1%-49% VS >50%). The', 'original study design is depicted in Figure 1 (Initial Treatment Phase).', 'As of Amendment 007-06, lenvatinib and matching placebo have been removed from the', 'treatment arms (Figure 1). All participants remaining on treatment in the study will receive', 'open-label pembrolizumab monotherapy. Treatment with pembrolizumab will continue up to', 'Cycle 35 or until reaching a discontinuation criterion (defined in Section 7.1). Imaging will', 'continue until progression by local investigator has been determined.', 'Participants will be evaluated with radiographic imaging to assess response to treatment', 'every 9 weeks from randomization through 54 weeks, then every 12 weeks until PD,', 'initiation of a new anticancer regimen, or completion of 35 cycles. All imaging obtained on', 'study will be submitted to the imaging vendor for BICR, which will assess the images using', 'RECIST 1.1 (see Section 8.2.1.5) for determination of OR, PFS, and DOR. After amendment', '007-06, imaging obtained on study will be submitted to the imaging vendor but these will not', 'be assessed, similarly, verification of PD is no longer needed before treatment', 'discontinuation. Treatment-based decisions may use site-assessed iRECIST, as described in', 'Section 8.2.1.6, which allows for participants with initial site-assessed PD to continue', 'treatment until PD is confirmed by the site 4 to 8 weeks later.', 'Adverse event monitoring will be ongoing throughout the study, and AEs will be graded by', 'severity according to the guidelines outlined in the National Cancer Institute (NCI) Common', 'Terminology Criteria for Adverse Events (CTCAE), version 4.0.', 'The study will be conducted in conformance with Good Clinical Practice (GCP).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}